Alligator Bioscience AB (0RK9)
LSE
Real-time Data
07:00 AM
Day's Range
0.023452 wk Range
0.0224Overview - 0RK9 - Alligator Bioscience AB
Key Statistics
Valuation
Enterprise Value
18.68M
P/E (Trailing)
‪-0.15‬
Price / Sales (TTM)
‪0.0055‬
Price / Book
‪0.46‬
EV / EBITDA
‪-0.22‬
Profitability
Gross Margin
‪64.14%‬
Profit Margin
‪60.19%‬
Operating Margin
‪-18,215.30%‬
Return on Assets
‪-62.91%‬
Return on Equity
‪10.43%‬
Ownership
Shares Outstanding
71.38M
Float
613.86M
Held by Insiders
‪1.65%‬
Held by Institutions
‪2.71%‬
Price stats
Beta
‪1.18‬
50-Day Avg
‪0.6220‬
200-Day Avg
‪0.6114‬
Market Cap - 0RK9 - Alligator Bioscience AB
Peers - 0RK9 - Alligator Bioscience AB
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0RK9LSEAlligator Bioscience AB2.39MMarket Cap-11328.57%52-week change-0.16P/E (Trailing)‪60.19%‬Profit Margin
- 0MGBLSEGenmab A/S168.08BMarket Cap+14.99%52-week change29.66P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock129.81BMarket Cap+24.36%52-week change0.54P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.84.57BMarket Cap+27.23%52-week change0.11P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna Inc.70.30BMarket Cap+83.56%52-week change53.96P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE50.13BMarket Cap+25.52%52-week change40.43P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA42.62BMarket Cap+1.46%52-week change123.24P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0RK9 - Alligator Bioscience AB
About
Alligator Bioscience AB is a clinical-stage biotechnology company focused on developing tumor-directed immuno-oncology antibody drugs, particularly those targeting the CD40 receptor pathway. Its primary purpose is to activate the patient's immune system directly within the tumor microenvironment, overcoming immune…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
